Phase I/II Trial of a Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral ß-glucan for High-Risk Neuroblastoma.

Trial Profile

Phase I/II Trial of a Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral ß-glucan for High-Risk Neuroblastoma.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Neuroblastoma vaccine (Primary) ; OPT 821 (Primary) ; Beta Glucans
  • Indications Neuroblastoma
  • Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 21 Nov 2016 Planned number of patients changed from 115 to 145.
    • 03 May 2016 Planned End Date changed from 1 May 2016 to 1 May 2020.
    • 03 May 2016 Planned primary completion date changed from 1 May 2016 to 1 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top